---
title: "Hyperion DeFi, Inc. (HYPD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HYPD.US.md"
symbol: "HYPD.US"
name: "Hyperion DeFi, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:38:16.011Z"
locales:
  - [en](https://longbridge.com/en/quote/HYPD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HYPD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HYPD.US.md)
---

# Hyperion DeFi, Inc. (HYPD.US)

## Company Overview

Hyperion DeFi, Inc. operates as a digital asset treasury and ophthalmic technology company in the United States. It operates through two segments: Ophthalmic Technology and Digital Assets. The company focuses on the long-term strategic treasury of HYPE tokens to provide simplified exposure to the Hyperliquid blockchain ecosystem.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [yperiondefi.com](https://yperiondefi.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.45)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 97 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1455.26% |  |
| Net Profit YoY | 4.95% |  |
| P/B Ratio | 0.67 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 39130300.58 |  |
| Revenue | 1043006.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -165.15% | E |
| Profit Margin | -3163.01% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 1455.26% | A |
| Net Profit YoY | 4.95% | C |
| Total Assets YoY | 1070.90% | A |
| Net Assets YoY | 702.17% | A |
| Cash Flow Margin | 36.06% | D |
| OCF YoY | 1455.26% | A |
| Turnover | 0.03 | E |
| Gearing Ratio | 16.51% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hyperion DeFi, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1455.26%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "4.95%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.67",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "39130300.58",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1043006.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-165.15%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-3163.01%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1455.26%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "4.95%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "1070.90%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "702.17%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "36.06%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "1455.26%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.03",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "16.51%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.97 | 102/189 | - | - | - |
| PB | 0.67 | 27/189 | 1.22 | 0.65 | 0.39 |
| PS (TTM) | 37.52 | 136/189 | 980.33 | 91.12 | 69.11 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.44 |
| Highest Target | 8.25 |
| Lowest Target | 4.30 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HYPD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HYPD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HYPD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HYPD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**